
CDSCO approves Leqembi for early Alzheimer's treatment in India
The story in brief
The Central Drugs Standard Control Organisation (CDSCO) has approved Eisai’s Leqembi for early Alzheimer’s treatment in India, marking a significant step in managing the disease. The drug, a humanised monoclonal antibody targeting amyloid-beta, requires amyloid pathology confirmation via CSF or serum biomarkers. Eisai plans structured patient support programmes to enhance affordability and access.